有机化学 ›› 2025, Vol. 45 ›› Issue (12): 4362-4374.DOI: 10.6023/cjoc202504013 上一篇    下一篇

研究论文

新型酰亚胺-β-咔啉的设计、合成及其抗肿瘤活性研究

邱东平, 王兆旭, 张洁*(), 郭亮*()   

  1. 石河子大学化学化工学院 化工绿色过程兵团重点实验室 化工绿色过程兵团重点实验室 新疆石河子 832003
  • 收稿日期:2025-04-12 修回日期:2025-06-27 发布日期:2025-08-18
  • 通讯作者: 张洁, 郭亮
  • 基金资助:
    国家自然科学基金(22067017); 新疆生产建设兵团指导计划(2022ZD019); 新疆生产建设兵团指导计划(2023ZD073); 新疆生产建设兵团科技攻关(2023AB047); 新疆生产建设兵团科技攻关(2023AB054); 新疆科技重大专项(2022A02006-5)

Design, Synthesis and Antitumor Activity of Novel Imide-β-carboline

Dongping Qiu, Zhaoxu Wang, Jie Zhang*(), Liang Guo*()   

  1. Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, School of Chemistry and Chemical Engineering, Shihezi University, Shihezi, Xinjiang 832003
  • Received:2025-04-12 Revised:2025-06-27 Published:2025-08-18
  • Contact: Jie Zhang, Liang Guo
  • Supported by:
    National Natural Science Foundation of China(22067017); Guidance Plan Project of Xinjiang Production and Construction Corps(2022ZD019); Guidance Plan Project of Xinjiang Production and Construction Corps(2023ZD073); Science and Technology Research Projects of Xinjiang Production and Construction Corps(2023AB047); Science and Technology Research Projects of Xinjiang Production and Construction Corps(2023AB054); Xinjiang Science and Technology Major Project(2022A02006-5)

为探寻更优异抗肿瘤活性的新颖化合物, 设计并合成了30个具有不同取代基的6-(N-酰亚胺)-β-咔啉衍生物, 通过甲基噻唑基四唑(MTT)法测试了目标化合物对肺癌细胞(A549)、胃癌细胞(BGC-823)、结肠癌细胞(CT-26)、肝癌细胞(Bel-7402)和乳腺癌细胞(MCF-7)的体外抗肿瘤活性. 实验结果表明, 该系列大部分化合物对被测试的癌细胞系展现出良好的抗肿瘤活性, 其半数抑止浓度(IC50)值低于20 μmol/L. 此外, 目标化合物对A549细胞系和Bel-7402细胞系显示出较好的抑制活性, 特别是化合物5j5p5ac对肿瘤细胞展现出较好的抑制活性, 具有潜在的抗肿瘤研究价值. 其中化合物5j5p对A549、BGC-823和Bel-7402细胞系表现出较优的抑制活性; 化合物5ac对A549、Bel-7402和MCF-7细胞系表现出较优的抑制活性, 其IC50值均小于10 μmol/L. 分子对接分析揭示, 化合物5ac与血管内皮生长因子受体-2(VEGFR-2)的多个氨基酸残基之间存在良好的相互作用.

关键词: β-咔啉, 酰亚胺, 抗肿瘤, 分子对接

In order to find novel compounds with superior antitumor activity, a series of 6-(N-imide)-β-carboline derivatives with diverse substituents, totaling 30 compounds, were designed and synthesized. The inhibitory effects of these compounds on five cancer cell lines, namely lung cancer (A549), gastric cancer (BGC-823), colon cancer (CT-26), liver cancer (Bel-7402), and breast cancer (MCF-7), were evaluated using methyl thiazolyl tetrazolium (MTT) assay. The experimental results indicated that most target compounds exhibit better antitumor activity against the tested cell lines, with half-maximal inhibitory concentrations (IC50) values below 20 μmol/L. Moreover, the series of compounds showed better inhibitory activity against the A549 and Bel-7402 cell lines. In particular, compounds 5j, 5p, and 5ac exhibited excellent inhibitory activity against tumor cells, demonstrating potential value for antitumor research. Specifically, compounds 5j and 5p exhibited excellent inhibitory activity against the A549, BGC-823, and Bel-7402 cell lines, while compound 5ac showed excellent inhibitory activity against the A549, Bel-7402, and MCF-7 cell lines, all with IC50 values less than 10 μmol/L. The molecular docking results indicate that compound 5ac exhibits favorable binding interactions with multiple amino acid residues of vascular endothelial growth factor receptor-2 (VEGFR-2).

Key words: β-carboline, imide, antitumor, molecular docking